LeMaitre Vascular, Inc. (LMAT)

Market Cap	2.61B +36.9%
Revenue (ttm)	249.60M +13.5%
Net Income	57.73M +31.1%
EPS	2.52 +30.6%
Shares Out	22.78M
PE Ratio	45.48
Forward PE	39.46
Dividend	$1.00 (0.87%)
Ex-Dividend Date	Mar 12, 2026

Volume	171,365
Open	113.00
Previous Close	112.71
Day's Range	112.24 - 114.94
52-Week Range	78.01 - 115.33
Beta	0.67
Analysts	Buy
Price Target	105.80 (-7.69%)
Earnings Date	Apr 30, 2026

About LMAT

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheter...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Oct 19, 2006
• Employees: 655
• Stock Exchange: NASDAQ
• Ticker Symbol: LMAT
• Website: https://www.lemaitre.com

Financial Performance

In 2025, LeMaitre Vascular's revenue was $249.60 million, an increase of 13.53% compared to the previous year's $219.86 million. Earnings were $57.73 million, an increase of 31.10%.

Analyst Summary

According to 5 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price target is $105.8, which is a decrease of -7.69% from the latest price.

Price Target

$105.8

(-7.69% downside)

Analyst Consensus: Buy